Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Nutriband Inc.

Market Cap 37.2M 32.09M 29.5M 27.77M 52.18M 3.51B 52.62M 350M 136M 1.72B 140M 137M 5.96B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 32.87M 28.36M 26.07M 24.54M 46.11M 3.1B 46.49M 309M 120M 1.52B 123M 121M 5.27B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
25.47%
Yield 2025 *
-
Yield 2026 -
1 day-7.55%
1 week-10.26%
Current month-12.32%
1 month-15.00%
3 months-21.74%
6 months-30.45%
Current year-32.60%
1 week 3.06
Extreme 3.06
3.52
1 month 3.06
Extreme 3.06
3.69
Current year 3.06
Extreme 3.06
4.98
1 year 3.06
Extreme 3.06
11.68
3 years 1.53
Extreme 1.53
11.78
5 years 1.53
Extreme 1.53
12.86
10 years 0.86
Extreme 0.8571
43.54
Manager TitleAgeSince
Chief Executive Officer 35 2015-12-31
Chief Executive Officer 52 -
Director of Finance/CFO 77 2020-09-01
Director TitleAgeSince
Chairman 52 2022-01-20
Director/Board Member 48 2018-06-30
Director/Board Member 35 2015-12-31
Date Insider Type Main position Quantity % Market Cap.
25-01-30Option

Chief Financial Officer

212,837 1.9164%
25-01-30Other

Founder

126,833 1.1420%
24-03-19Free

Founder

97,500 1.2447%
Change 5-day change 1-year change 3-year change Capi.($)
-7.55%-10.26%-60.52%+17.69% 40.24M
-2.34%-0.75%-33.10%-16.67% 158B
-3.91%-2.63%-9.32%-12.35% 104B
+2.53%+10.53%+65.35%+62.42% 56.43B
-1.55%-1.48%-5.49%+51.41% 54.76B
-2.45%-4.18%-16.67%-45.25% 40B
-1.81%-0.33% - - 31.36B
-2.64%-4.73%-12.95%-45.25% 28.23B
-1.82%-2.22%+48.39%-10.62% 23.28B
-0.33%-0.97%-14.77%-4.68% 20.41B
Average -2.16%-2.08%-4.34%-0.37% 51.68B
Weighted average by Cap. -1.91%-0.85%-6.22%-2.09%

Financials

2025 2026
Net sales 2.14M 1.85M 1.7M 1.6M 3M 202M 3.03M 20.11M 7.83M 99.1M 8.03M 7.86M 343M 2.04M 1.76M 1.62M 1.52M 2.86M 192M 2.88M 19.14M 7.45M 94.33M 7.64M 7.48M 326M
Net income -10.48M -9.04M -8.31M -7.83M -14.71M -989M -14.83M -98.53M -38.36M -486M -39.34M -38.5M -1.68B -8.23M -7.1M -6.53M -6.14M -11.54M -777M -11.64M -77.35M -30.12M -381M -30.89M -30.23M -1.32B
Net Debt -4.13M -3.56M -3.27M -3.08M -5.79M -389M -5.84M -38.78M -15.1M -191M -15.48M -15.15M -661M -4.33M -3.73M -3.43M -3.23M -6.07M -409M -6.12M -40.69M -15.84M -201M -16.25M -15.9M -694M
Logo Nutriband Inc.
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-
Date Price Change Volume
26-06-17 3.060 $ -7.55% 5,982
26-06-16 3.310 $ -2.93% 17,017
26-06-15 3.410 $ +0.59% 4,363
26-06-12 3.390 $ -3.69% 6,289
26-06-11 3.520 $ +3.23% 4,961
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.060USD
Average target price
15.00USD
Spread / Average Target
+390.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRB Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!